<DOC>
	<DOCNO>NCT01872962</DOCNO>
	<brief_summary>The purpose study compare induction chemotherapy ( gemcitabine+cisplatin ) plus concurrent chemoradiotherapy ( CCRT ) CCRT alone patient locoregionally advanced nasopharyngeal carcinoma ( NPC ) , order confirm value induction chemotherapy NPC patient .</brief_summary>
	<brief_title>Induction Gemcitabine Cisplatin Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Patients Patients non-keratinizing NPC T3-4N1M0/TxN2-3M0 ( UICC/AJCC 7th edition ) randomly assign receive induction chemotherapy plus CCRT CCRT alone . Patients group receive cisplatin 100 mg/m² every 3 week 3 cycle , concurrently intensity-modulated radiotherapy ( IMRT ) . IMRT give 2.0-2.30 Gy per fraction five daily fraction per week 6-7 week total dose 66 Gy great primary tumor . The induction chemotherapy plus CCRT group receive gemcitabine ( 1000 mg/m² d1,8 ) cisplatin ( 80mg/m² d1 ) every 3 week three cycle CCRT . Our primary endpoint failure-free survival ( FFS ) . Secondary end point include overall survival ( OS ) , locoregional failure-free survival ( LR-FFS ) , distant failure-free survival ( D-FFS ) rate toxic effect . All efficacy analysis conduct intention-to-treat population , safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients newly histologically confirm nonkeratinizing ( accord WHO histologically type ) . Tumor stag T34N1/N23 ( accord 7th AJCC edition ) . No evidence distant metastasis ( M0 ) . Satisfactory performance status : Karnofsky scale ( KPS ) ≥ 70 . Adequate marrow : leucocyte count ≥ 4000/μL , hemoglobin ≥ 90g/L platelet count ≥ 100000/μL . Normal liver function test : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) &lt; 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤ 2.5×ULN , bilirubin ≤ ULN . Adequate renal function : creatinine clearance ≥ 60 ml/min . Patients must inform investigational nature study give write informed consent . WHO Type keratinize squamous cell carcinoma basaloid squamous cell carcinoma . Age &gt; 65 &lt; 18 . Treatment palliative intent . Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . History previous RT ( except nonmelanomatous skin cancer outside intend RT treatment volume ) . Prior chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Clinical trial</keyword>
</DOC>